Showing results (211-220 of 531) with videos related to
Sort By:
Pageof 54
Circulation|February 6, 2002
Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different?K Martijn Akkerhuis, John H Alexander, Barbara E Tardiff, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|November 28, 2002
Reduction in vascular access site bleeding in sequential abciximab coronary intervention trialsJames C Blankenship, Craig Balog, Shelly K Sapp, et al.European Heart Journal. Acute Cardiovascular Care|June 8, 2018
Clevidipine as a therapeutic and cost-effective alternative to sodium nitroprusside in patients with acute aortic syndromesCarlos L Alviar, Alejandra Gutierrez, Leslie Cho, et al.The Journal of Thoracic and Cardiovascular Surgery|June 9, 2005
Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: results of a pilot studyAndreas Koster, Ruhi Yeter, Semih Buz, et al.BMC Nephrology|November 20, 2014
Effects of the dual peroxisome proliferator-activated receptor-α/γ agonist aleglitazar on renal function in patients with stage 3 chronic kidney disease and type 2 diabetes: a Phase IIb, randomized studyLuis Ruilope, Markolf Hanefeld, A Michael Lincoff, et al.Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|July 29, 2010
Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosisInder M Singh, Steven J Filby, Fredy El Sakr, et al.Circulation|November 28, 2001
beta-blockers before percutaneous coronary intervention do not attenuate postprocedural creatine kinase isoenzyme riseS G Ellis, S J Brener, A M Lincoff, et al.Journal of the American College of Cardiology|November 20, 1998
Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. EPIC and EPILOG Investigators. Evaluation of 7E3 for the Prevention of Ischemic Complications. Evaluation of PTCA To Improve Long-term Outcome with abciximab GPIIb/IIIa Receptor BlockadeS G Ellis, A M Lincoff, D Miller, et al.American Heart Journal|January 30, 1999
Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC InvestigatorsM C Thel, R M Califf, J E Tcheng, et al.Circulation|February 9, 1999
Rapid platelet-function assay: an automated and quantitative cartridge-based methodJ W Smith, S R Steinhubl, A M Lincoff, et al.Pageof 54